论文部分内容阅读
目的观察半乳糖化白蛋白磁性阿霉素纳米粒(ADR-GHMN)在正常肝脏中的靶向性, 并观察ADR-GHMN在全身各脏器的分布特征。方法使用放射示踪技术,用125I标记纳米粒。肝动脉注射,分别于注药后5、15、30、60、120 min处死,立即取肝、肾、心、肺、小肠、脾、及周围血作γ计数。结果半乳糖化白蛋白磁性阿霉素纳米粒在注射后5 min后最高,为15054.4 CPM/g,各时相前者的肝摄取率均为同时刻后者的2,3倍。两药在肝、肾、心、肺、小肠、脾、及周围血的分布有高度显著性(P<0.05)。结论半乳糖化白蛋白磁性阿霉素纳米粒在正常肝组织中有明显的主动靶向性,半乳糖化白蛋白磁性阿霉素纳米粒主要分布肝脏,其它的脏器含量少。
Objective To observe the targeting of galactosylated albumin magnetic doxorubicin nanoparticles (ADR-GHMN) in normal liver and to observe the distribution characteristics of ADR-GHMN in various organs of the body. Methods Using radioactive tracing techniques, nanoparticles were labeled with 125I. Hepatic artery injection, respectively, after injection of 5,15,30,60,120 min death, immediately take liver, kidney, heart, lung, small intestine, spleen, and peripheral blood for γ count. Results The galactosylbumin magnetic doxorubicin nanoparticles reached the highest level at 15054.4 CPM / g 5 min after injection, and the hepatic uptake rate of the former was 2,3 times higher than that of the latter at the same time. The distribution of the two drugs in liver, kidney, heart, lung, small intestine, spleen and peripheral blood was highly significant (P <0.05). Conclusions Galactosylbumin magnetic doxorubicin nanoparticles have obvious active targeting in normal liver tissue. Galactosylbumin magnetic doxorubicin nanoparticles mainly distribute in the liver, while other organs have less content.